# Nancy Paul Roc

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/nancy-paul-roc/

## Facts

| Field | Value |
| --- | --- |
| Citations | 24 |
| Field | Chronic Lymphocytic Leukemia Research |
| h-index | 1 |
| i10-index | 1 |
| Last Known Institution | ABB (Canada) |
| OpenAlex ID | https://openalex.org/A5045435141 |
| Works | 9 |

## Researcher papers

- [Early access for innovative oncology medicines: a different story in each nation](https://scholariq.org/papers/early-access-for-innovative-oncology-medicines-a-different-story-in-each-nation/)
- [The Economic Impact of Treatment Sequencing in Chronic Lymphocytic Leukemia in Canada Using Venetoclax plus Obinutuzumab](https://scholariq.org/papers/the-economic-impact-of-treatment-sequencing-in-chronic-lymphocytic-leukemia-in/)
- [The Economic Impact of Treatment Sequencing in the Management of Chronic Lymphocytic Leukemia in Canada Using Venetoclax Plus Obinutuzumab](https://scholariq.org/papers/the-economic-impact-of-treatment-sequencing-in-the-management-of-chronic/)
- [Costs of Healthcare Resource Utilization in the Management of Patients with Higher-Risk Myelodysplastic Syndrome in Canada](https://scholariq.org/papers/costs-of-healthcare-resource-utilization-in-the-management-of-patients-with/)
- [Time-limited reimbursement and Temporary Access Process for early access to oncology treatments in Canada: a perspective based on the epcoritamab experience](https://scholariq.org/papers/time-limited-reimbursement-and-temporary-access-process-for-early-access-to/)
- [Healthcare resource use in the management of advanced epithelial ovarian cancer in Canada.](https://scholariq.org/papers/healthcare-resource-use-in-the-management-of-advanced-epithelial-ovarian-cancer/)
- [EE355 Healthcare Resource Utilization in the Management of Patients with Relapse/Refractory Mantle Cell Lymphoma in Canada](https://scholariq.org/papers/ee355-healthcare-resource-utilization-in-the-management-of-patients-with-relapse/)
- [Venetoclax in Combination with Obinutuzumab in Previously Untreated Fit Patients with Chronic Lymphocytic Leukemia: A Canadian Cost-Utility Analysis](https://scholariq.org/papers/venetoclax-in-combination-with-obinutuzumab-in-previously-untreated-fit-patients/)
- [Health care resource use in the management of patients with relapsed/refractory diffuse large B-cell lymphoma – Canadian perspective](https://scholariq.org/papers/health-care-resource-use-in-the-management-of-patients-with-relapsed-refractory/)

## Researcher topics

- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Economic and Financial Impacts of Cancer](https://scholariq.org/topics/economic-and-financial-impacts-of-cancer/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

## Researcher university

- [ABB (Canada)](https://scholariq.org/institutions/abb-canada/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.